Evidence map›Paper›PMID 22475628›Full record

ArticleJournal of biomedical science2012

Down-regulation of PKCζ in renal cell carcinoma and its clinicopathological implications.

Yeong-Shiau Pu, Chao-Yuan Huang, Jyue-Yu Chen, Wang-Yi Kang, Ying-Chu Lin, Yu-Shiang Shiu, Shu-Ju Chuang, Hong-Jeng Yu, Ming-Kuen Lai, Yu-Chieh Tsai and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Journal of biomedical science, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. High Expression ofCancer genomics & proteomics · 2025
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. HOIL-1L functions as the PKCζ ubiquitin ligase to promote lung tumor growth.American journal of respiratory and critical care medicine · 2014
    Article
  8. Article
  9. c-Myc phosphorylation by PKCζ represses prostate tumorigenesis.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Article
  10. Article
  11. Cancer diagnosis & prognosis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Yeong-Shiau PuDepartment of Urology, National Taiwan University College of Medicine, Taipei, Taiwan.
Chao-Yuan Huang
Jyue-Yu Chen
Wang-Yi Kang
Ying-Chu Lin
Yu-Shiang Shiu
Shu-Ju Chuang
Hong-Jeng Yu
Ming-Kuen Lai
Yu-Chieh Tsai
Wen-Jeng Wu
Tzyh-Chyuan Hour
Kaohsiung Medical University · TWNational Taiwan University · TWKaohsiung Medical University Chung-Ho Memorial Hospital · TWKuo General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetastatic renal cell carcinoma (RCC) is highly resistant to systemic chemotherapy. Unfortunately, nearly all patients die of the metastatic and chemoresistant RCC. Recent studies have shown the atypical PKCζ is an important regulator of tumorigenesis. However, the correlation between PKCζ expression and the clinical outcome in RCC patients is unclear. We examined the level of PKCζ expression in human RCC.

methodsPKCζ mRNA and protein expressions were examined by real-time polymerase chain reaction (PCR) and immunohistochemistry (IHC) respectively in RCC tissues of 144 patients. Cellular cytotoxicity and proliferation were assessed by MTT.

resultsPKCζ expression was significantly higher in normal than in cancerous tissues (P<0.0001) by real-time PCR and IHC. Similarly, PKCζ expression was down-regulated in four renal cancer cell lines compared to immortalized benign renal tubular cells. Interestingly, an increase of PKCζ expression was associated with the elevated tumor grade (P=0.04), but no such association was found in TNM stage (P=0.13). Tumors with higher PKCζ expression were associated with tumor size (P=0.048). Expression of higher PKCζ found a poor survival in patients with high tumor grade. Down-regulation of PKCζ showed the significant chemoresistance in RCC cell lines. Inactivation of PKCζ expression enhanced cellular resistance to cisplatin and paclitaxel, and proliferation in HK-2 cells by specific PKCζ siRNA and inhibitor.

conclusionsPKCζ expression was associated with tumorigenesis and chemoresistance in RCC.

Indexed as

Drug Resistance, NeoplasmGene Expression Regulation, NeoplasticAgedCarcinoma, Renal CellCell Line, TumorCell ProliferationCisplatinDown-RegulationFemaleFormazansGene Knockdown TechniquesHumansImmunohistochemistryKidney NeoplasmsMaleMiddle AgedCisplatinFormazansMTT formazanPaclitaxelProtein Kinase CProtein Kinase C zetaRNA, MessengerRNA, Small InterferingTetrazolium Salts

Identifiers

PMID22475628
PMCPMC3376037
OpenAlexW2128596262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.